Esmolol nonclinical toxicology: Difference between revisions

Revision as of 19:38, 4 February 2014

Esmolol
BREVIBLOC^® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]

Because of its short term usage non of the followings have been studied:^[1]

Adapted from the FDA Package Insert.

@@ Line 4: / Line 4: @@
 ==Nonclinical Toxicology==
-Because of its short term usage no carcinogenicity, mutagenicity, or reproductive performance studies have been conducted with esmolol.<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = BREVIBLOC (ESMOLOL HYDROCHLORIDE) INJECTION [BAXTER HEALTHCARE CORPORATION] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=595cc3d5-1306-4828-aefa-5595219ffd62 | publisher =  | date =  | accessdate = }}</ref>
+Because of its short term usage non of the followings have been studied:<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = BREVIBLOC (ESMOLOL HYDROCHLORIDE) INJECTION [BAXTER HEALTHCARE CORPORATION] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=595cc3d5-1306-4828-aefa-5595219ffd62 | publisher =  | date =  | accessdate = }}</ref>
+:*'''Carcinogenicity'''
+:*'''Mutagenicity'''
+:*'''Fertility'''
 ==References==